Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Kober

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Journal of the American College of Cardiology|June 29, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
European Heart Journal|June 29, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
Global Heart|July 6, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
European Heart Journal|January 12, 2023
Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fractionJames P Curtain, Carly Adamson, Toru Kondo, et al.
Journal of the American College of Cardiology|February 2, 2013
Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity"Thais Coutinho, Kashish Goel, Daniel Corrêa de Sá, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
Journal of Cardiac Failure|August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trialDavid D Berg, Kieran Docherty, Atefeh Talebi, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Journal of the American College of Cardiology|June 29, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
European Heart Journal|June 29, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
Global Heart|July 6, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
European Heart Journal|January 12, 2023
Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fractionJames P Curtain, Carly Adamson, Toru Kondo, et al.
Journal of the American College of Cardiology|February 2, 2013
Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity"Thais Coutinho, Kashish Goel, Daniel Corrêa de Sá, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
Journal of Cardiac Failure|August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trialDavid D Berg, Kieran Docherty, Atefeh Talebi, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 11